Enclave Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Enclave Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$237K	Buy	+1,502	New	+$237K	0.03%	124

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $20.7B AUM 58.31% 1-Year Est. Return

Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return

Enclave Advisors's XBI Position: Q3 2026 in Review

Enclave Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 1,502 shares worth $237K. The stake represents 0.03% of the portfolio and ranks #124 among its holdings.

622 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Enclave Advisors held 1,502 shares of State Street SPDR S&P Biotech ETF worth $237K as of Q3 2026.
State Street SPDR S&P Biotech ETF was a new Enclave Advisors position in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.03% of Enclave Advisors's portfolio in Q3 2026, its #124 holding.
622 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Enclave Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.